At a panel billed "Predict. Prevent. Personalise," Australian leaders in general practice, pathology, genetics and consumer advocacy, joined by a visiting health economist, agreed prevention already works. What's missing, they found, is a funding model and a delivery system built for a country this large and this uneven.

After waiting lists pushed Denmark’s public health system to breaking point in the mid-2000s, the country’s first instinct was to build more hospitals. Nearly two decades on, former Healthcare Denmark chief Hans Erik Henriksen says the harder, more important work was deciding where care should happen at all.

As regulatory complexity accelerates, Regulatory Affairs leaders face a hard question: can existing teams keep pace through more effort alone, or does the function now need to be redesigned around intelligent, governed automation?

A vehicle dynamics engineer who once tuned 700 horsepower supercars now wants to make clinical trial software as intuitive as opening a social media app. His story says as much about where the sector is heading as it does about one founder's pivot.

A Pre-Conference Edition That Captures a Sector in Motion

There is something fitting about a magazine called Cognitio arriving at this particular moment. The word means knowledge, and knowledge, as this edition makes clear, is precisely what Australia's life sciences sector is being asked to generate, apply, and rethink at pace.

Australia's Medical Research Future Fund has finally broken free of its $650 million spending freeze. The path to $1 billion has been announced, but it leads to 2030, not today.

A panel of investors, economists and sector specialists gathered in Sydney to confront an uncomfortable truth: Australia is world-class at creating medical technology, and world-class at failing to commercialise it.

Japan’s latest five-year health and medical R&D strategy offers a timely case study for Australia’s own life sciences ecosystem, particularly as we continue to confront familiar challenges around clinical trial competitiveness, translational capability, sovereign capability and access to innovation.

Australia has one of the highest rates of skin cancer in the world. Around 2,000 Australians die each year from melanoma and related conditions. Sunscreen is not just a consumer product in this context, it is a frontline public health intervention.

Australia is not moving fast enough in the effective use of generative AI (genAI), and professionals across the therapeutic goods sector. The time to engage with AI is now, not after everyone else has figured it out.

Artificial intelligence is making significant strides in medical research, with a recent development in regenerative medicine highlighting its potential to transform healthcare

As clinical trials grow more complex, so too does the burden placed on the workforce responsible for delivering them. The BALANCE Project was developed to address this gap